Optimal blood pressure on antihypertensive medication
- John M. Flack MD, MPH
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The optimal blood pressure (BP) level for a patient on antihypertensive medication should maximize the patient’s well-being and simultaneously lower the risk for pressurerelated cardiovascular-renal complications. The clinical expression of pressure-related complications such as stroke, heart failure, renal insufficiency, peripheral arterial disease, and cognitive decline takes many years to decades to manifest. Accordingly, the attainment of the ultimate target BP is rarely necessary, or even desirable, over short time periods (eg, weeks) because the absolute clinical risk within these time periods is quite low. However, overmedication or aggressive BP lowering over the short term increases the likelihood of treatment-related side effects. Thus, attainment of goal BP should be accomplished gradually over many weeks to months in order to maximize BP lowering at a given dose of medication(s). Recent target BP goals promulgated by the Sixth Report from the Joint National Committee (JNC VI) are based on the premise that the intensity of treatment directly corresponds to the magnitude of pretreatment risk. Thus, hypertensive persons with diabetes, renal disease, or heart failure have goal BP levels lower than 130/85 mm Hg. All other hypertensive individuals should attain BP levels minimally to lower than 140/90 mm Hg. Finally, there is now appropriate recognition of the pivotal role of BP reduction in forestalling pressure-related cardiovascular complications, even among high-risk persons with diabetes mellitus and renal insufficiency.
- Flack JM, Sisson L, Gardin JM, Yunis C, Liu K: Static and pulsatile blood pressure correlates of left ventricular structure in a biethnic cohort of young adults: the CARDIA Study. Am Heart J (In press).
- Flack JM, Neaton JD, Daniels B, Esunge P: Ethnicity and renal disease: lessons from multiple risk factor intervention trial and the Treatment of Mild Hypertension Study. Am J Kidney Dis 1993, 21(suppl 1):31–40.
- Flack JM, Neaton JD, Grimm RH Jr, et al.: Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995, 9:2437–2445.
- MacMahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease, I: prolonged differences in blood pressure--prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765–774. CrossRef
- Klag MJ, Whelton PK, Randall BL, et al.: End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA 1997, 277:1293–1298. CrossRef
- Haider AW, Chen L, Larson MG, et al.: Antecedent hypertension confers increased risk for adverse outcomes after initial myocardial infarction. Hypertension 1997, 30:1020–1024.
- Neaton JD, Grimm RH Jr, Prineas RJ, et al.: Treatment of Mild Hypertension Study. JAMA 1993, 270:713–724. CrossRef
- Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) Randomised Trial. Lancet 1998, 351:1755–1762. There was no confirmation of a treatment-induced J-curve in this large prospective clinical trial that used a dihydropyridine calcium antagonist as the initial antihypertensive drug therapy, neither in the overall cohort nor in those with coronary heart disease at baseline. Persons with diabetes mellitus experienced greater treatment benefits than persons without diabetes. The nadir of risk for major cardiovascular events and stroke hovered around the hypertension threshold (140/90 mm Hg). CrossRef
- Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for the older patients with isolated hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial investigators. Lancet 1997, 350:757–764. CrossRef
- Final results of the Systolic Hypertension in the Elderly Program (SHEP): prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991, 265:3255–3264.
- UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998, 317:703–713. This important study demonstrated the tremendous importance of BP lowering among persons with type 2 diabetes mellitus. Interestingly, BP remained well above the current JNC VI recommended target BP level of 130/85 mm Hg.
- Pearce KA, Furberg CD, Rushing J: Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials. Arch Fam Med 1995, 4:943–950. CrossRef
- Gueyffier F, Bulpitt C, Boissel JP, et al.: Antihypertensive drugs in very old people: A subgroup meta-analysis of randomised controlled trials. Lancet 1999, 353:793–796. CrossRef
- Multiple Risk Factor Intervention Trial Research Group: Mortality after 101/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial [MRFIT]. Circulation 1990, 82:1616–1628.
- Hypertension Detection and Follow-up Program Cooperative Group: Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. JAMA 1988, 259:2113–2122. CrossRef
- National High Blood Pressure Education Program: In The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health publication 98-4080, 1997:1–70.
- Thorp JM, Cruickshank JM, Zacharias FJ: Benefits and potential harm of lowering high blood pressure. Lancet 1987, 1:581–584.
- Sutton-Tyrrell K, Alcorn HG, Wolfson SK Jr, et al.: Predictors of carotid stenosis in older adults with and without isolated systolic hypertension. Stroke 1993, 24:355–361.
- Sutton-Tyrrell K, Alcorn HG, Herzog H, et al.: Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke 1995, 26:1319–1324.
- Sutton-Tyrrell K, Wolfson SK Jr, Kuller LH: Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke 1994, 25:44–50.
- Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986, 293:1145–1151. CrossRef
- Parving HH, Smidt UM, Andersen AR, Svendsen PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983, 1175–1178.
- Parving HH, Andersen AR, Smidt UM, et al.: Reduced albuminuria during early and aggressive antihypertensive treatment of insulin-dependent diabetic patients with diabetic nephropathy. Diabetes Care 1981, 4:459–463. CrossRef
- Weir MR, Dworkin LD: Antihypertensive drugs, dietary salt, and renal protection: how low should you go and with which therapy? Am J Kidney Dis 1998, 32:1–22.
- UK Prospective Diabetes Study Group: Efficacy of atenolol and captropril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998, 317:713–720. No difference in the occurrence of micro- or macrovascular complications was seen between the ACE inhibitor and the beta blocker treatment regimens. However, the ACE inhibitor-based treatment regimen was better tolerated over the long term. Three-drug therapy was needed in ∼ 30% of participants to achieve goal BP levels well above the current recommended target of minimally < 130/85 mm Hg.
- Curb JD, Pressel SL, Cutler JA, et al.: Effects of Diuretic-based Antihypertensive Treatment on Cardiovascular Disease Risk in Older Diabetic Patients With Isolated Systolic Hypertension. JAMA 1996, 276:1886–1892. CrossRef
- Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of Calcium-Channel Blockade in Older Patients With Diabetes and Systolic Hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340:677–684. CrossRef
- Hebert LA, Kusck JW, Greene T, et al.: Effects of blood pressure control on progressive renal disease in blacks and whites: Modification of Diet in Renal Disease Study Group. Hypertension 1997, 30(3 Pt 1):428–435.
- Giatras I, Lau J, Levey AS: Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997, 127:337–345.
- Flack JM, Yunis C, Preisser J, et al.: The Quinapril Titration Interval Management Evaluation (ATIME) trial. Am J Hypertension 1998, 11:103A. This study provided evidence of a constellation of symptoms that were more common at higher levels of BP, thereby supporting the notion that hypertension is truly not asymptomatic. More deliberate titration of the ACE inhibitor also was associated with improved subjective patient outcomes well as BP control. These data argue in favor of slow BP reductions and, as well, to not attribute all side effects reported by patients to their drug therapy. CrossRef
- Grimm RH Jr, Grandits GA, Cutler JA, et al.: Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 1997, 157:638–648. CrossRef
- Black DM, Brand RJ, Greenlick M, et al.: Compliance to treatment for hypertension in elderly patients: the SHEP Pilot Study. J Gerontol 1987, 42:552–557.
- Berlowitz DR, Ash AS, Hickey EC, et al.: Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998, 339:1957–1963. This retrospective medical review provided tremendous insight into the contribution of physician behavior to the poor levels of BP control observed in many clinic patients. However, what this study does not answer are the reasons why physicians do not intensify therapy when faced with poorly controlled BP levels. Nevertheless, this study is an important reminder of the provider’s role in achieving BP normalization. CrossRef
- Optimal blood pressure on antihypertensive medication
Current Hypertension Reports
Volume 1, Issue 5 , pp 381-386
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Departments of Internal Medicine and Community Medicine, Cardiovascular Epidemiology and Clinical Applications Program, Division of Endocrinology, Metabolism, and Hypertension, Wayne State University School of Medicine, 4201 St. Antoine, 2E, 48201, Detroit, MI, USA